Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Dec:26:1076029620960797.
doi: 10.1177/1076029620960797.

The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review

Indra Wijaya  1 , Rizky Andhika  2 , Ian Huang  2
Affiliations

The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review

Indra Wijaya et al. Clin Appl Thromb Hemost. 2020 Jan-Dec.

Abstract

The incidence of venous thromboembolism (VTE) events in patients with COVID-19 treated with a standard thromboprophylaxis dose of anticoagulants remains high. We conducted a systematic review in order to explore the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19. A systematic search was carried out using the electronic databases of PubMed, EuropePMC, and the Cochrane Central Database, using specific keywords. All articles that fulfilled the inclusion criteria were included in the qualitative analysis. There were 8 observational studies included in the final qualitative analysis. Quality assessment using the Newcastle-Ottawa Scale (NOS) showed a mean score of 7.5 ± 1.06, indicating moderate to high quality of the studies. Three retrospective cohort studies reported a reduction in the mortality rate, while 6 other studies showed no mortality benefits among patients with COVID-19 treated with therapeutic-dose anticoagulation. There was a slight tendency toward a reduction in the mortality rate among mechanically-ventilated patients with COVID-19 receiving therapeutic-dose anticoagulation. Bleeding events and thrombotic complications among patients receiving therapeutic-dose anticoagulation were reported in 3 studies. Although it is too soon to draw any conclusions, this systematic review draws attention to current evidence regarding the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19.

Keywords: COVID-19; SARS-CoV-2; anticoagulants; mortality; therapeutic-dose anticoagulation.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA guideline.
See this image and copyright information in PMC

References

    1. World Health Organization. Coronavirus Disease (COVID-19) Situation Report—187. Published 2020 Accessed July 27, 2020 https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...
    1. Pranata R, Soeroto AY, Huang I, et al. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19 [published online ahead of print]. Int J Tuberc Lung Dis. 2020. doi:10.5588/ijtld.20.0278 - PubMed
    1. Yonas E, Alwi I, Pranata R, et al. Effect of heart failure on the outcome of COVID-19—a meta analysis and systematic review. Am J Emerg Med. 2020;155:104743 doi:10.1016/j.ajem.2020.07.009 - PMC - PubMed
    1. Lim MA, Pranata R, Huang I, Yonas E, Soeroto AY, Supriyadi R. Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis. Can J Kidney Heal Dis. 2020;7(1):1–12. doi:10.1177/2054358120938 - PMC - PubMed
    1. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1–14. doi:10.1177/ 1753466620937175 - PMC - PubMed

Publication types